RPRX - Royalty Pharma plc
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$62.67
DETAILS
HIGH:
$66.00
LOW:
$57.00
MEDIAN:
$65.00
CONSENSUS:
$62.67
UPSIDE:
2.94%
About Royalty Pharma plc (https://www.royaltypharma.com)
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Pablo Legorreta | Founder, Chairman of the Board & Chief Executive Officer | 1963 | $44,019,342 USD |
| Arthur Richard McGivern | Executive Vice President of Investments & Chief Scientific Officer | 1975 | $3,395,000 USD |
| James Folmar Reddoch | Executive Vice President of Investments & Chief Scientific Officer | 1970 | $3,395,000 USD |
| Christopher Hite | Chairman of Partnering & Investments | 1967 | $1,323,000 USD |
| Marshall Urist | Head of Research & Investments | 1976 | $1,323,000 USD |
| Terrance Coyne | Executive Vice President & Chief Financial Officer | – | $1,323,000 USD |
| Eric Cornelius Schneider | Senior Vice President & Chief Technology Officer | – | – |
| George Grofik | Senior Vice President and Head of Investor Relations & Communications | – | – |
| Greg Butz | Executive Vice President of Partnering & Investments | – | – |
| Molly Sawaya | Executive Vice President & Head of Human Capital | – | – |
| Sandy Balkin | Senior Vice President of Strategy & Analytics | – | – |